Helicure was founded in 2005 and develops vaccines to cure peptic ulcer disease and to protect against gastric cancer, based on eradication of "bad" Helicobacter pylori infections. In the western world, up to 50% of the population is infected with Heliobacter pylori and the proportion considerably larger in Asia. By using proprietary attachment proteins from Heliobacter pylori as immunization agents, combined with immune stimulating adjuvants, oral or nasal vaccines will be created.


Contact: Thomas Borén, CEO

Contact details
BOX 7997, SE-90719 Umeå, Sweden